-
Small Trial of 24 Offers a Methodology for Tackling MS via Attacking EBV Virus,
As usual, this story would be years off and hasn’t even been peer-reviewed yet. I’m reporting it cos I’ve spent 2 hours researching it – so there.
There’s been oodles of science re EBCV & MS – we currently carry 82 stories about this on our home site.
‘A phase 1 clinical trial by the California-based immunotherapy company Atara Biotherapeutics confirms latent Epstein-Barr (EBV) infections are viable targets for treating MS in at least some patients, reinforcing a curious link between the virus and a deadly illness that affects millions around the world.
Out of the trial’s 24 volunteers, 20 showed signs of either improvement or at least a halt in their health’s steady decline. Importantly, there were no signs of serious side effects.
Any thoughts on this study?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.